Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ron Firestein

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
Molecular Cancer Therapeutics|October 21, 2016
Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPETAnton G T Terwisscha van Scheltinga, Annie Ogasawara, Glenn Pacheco, et al.
Plos One|April 17, 2008
The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growthRon Firestein, Gil Blander, Shaday Michan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2015
Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian CancerLisa Ryner, Yinghui Guan, Ron Firestein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2015
An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor MalignanciesJyoti Asundi, Lisa Crocker, Jarrod Tremayne, et al.
Cancers|October 23, 2021
Atypical Teratoid Rhabdoid Tumours Are Susceptible to Panobinostat-Mediated Differentiation TherapyWai C Chong, W Samantha N Jayasekara, Vijesh G Vaghjiani, et al.
British Journal of Pharmacology|August 15, 2012
An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2C Andrew Boswell, Eduardo E Mundo, Ron Firestein, et al.
Plos One|February 4, 2010
CK1epsilon is required for breast cancers dependent on beta-catenin activitySo Young Kim, Ian F Dunn, Ron Firestein, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8/19 Knockout CellsMichael F T Koehler, Philippe Bergeron, Elizabeth M Blackwood, et al.
Cancer Research|November 10, 2012
An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancerMark L McCleland, Adam S Adler, Yonglei Shang, et al.
ACS Medicinal Chemistry Letters|June 22, 2016
Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8Philippe Bergeron, Michael F T Koehler, Elizabeth M Blackwood, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Molecular Cancer Therapeutics|October 21, 2016
Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPETAnton G T Terwisscha van Scheltinga, Annie Ogasawara, Glenn Pacheco, et al.
Plos One|April 17, 2008
The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growthRon Firestein, Gil Blander, Shaday Michan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2015
Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian CancerLisa Ryner, Yinghui Guan, Ron Firestein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2015
An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor MalignanciesJyoti Asundi, Lisa Crocker, Jarrod Tremayne, et al.
Cancers|October 23, 2021
Atypical Teratoid Rhabdoid Tumours Are Susceptible to Panobinostat-Mediated Differentiation TherapyWai C Chong, W Samantha N Jayasekara, Vijesh G Vaghjiani, et al.
British Journal of Pharmacology|August 15, 2012
An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2C Andrew Boswell, Eduardo E Mundo, Ron Firestein, et al.
Plos One|February 4, 2010
CK1epsilon is required for breast cancers dependent on beta-catenin activitySo Young Kim, Ian F Dunn, Ron Firestein, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8/19 Knockout CellsMichael F T Koehler, Philippe Bergeron, Elizabeth M Blackwood, et al.
Cancer Research|November 10, 2012
An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancerMark L McCleland, Adam S Adler, Yonglei Shang, et al.
ACS Medicinal Chemistry Letters|June 22, 2016
Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8Philippe Bergeron, Michael F T Koehler, Elizabeth M Blackwood, et al.
Pageof 7